COP and BER also enhance the anticancer effect of estrogen receptor antagonists, including tamoxifen and fulvestrant, likely by regulating multiple cancer-related genes, e.g.EGFRHER2bcl-2COX-2, and p21[10]. The gene discussed is ESR1; the disease is cancer.